

# A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

NCT06413654

---

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Shanghai Jiaolian Drug Research and Development Co., Ltd
Enrollment	132 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Confirmed NMOSD patients;
- Experienced at least 1 recurrence of NMOSD within 1 year or at least 2 recurrence within 2 years prior to screening;
- The blood pregnancy tests were negative within 7 days before the first dose in fertile female subjects. The fertile subjects and the male subjects whose partner are fertile woman agree to use reliable contraception during the study period and within 6 months after the study drug discontinuation;
- Volunteer to participate in clinical research; Fully understand and know the study and sign the informed consent; Willing to follow and able to complete all test procedures.

### Exclusion (19)

- Subjects with severe NMOSD were judged by the researcher to be unfit to participate in this study;
- Subjects with chronic active immune system diseases undergoing systematic treatment;
- Received anti-CD20 or other cell depletion therapy within 6 months before first dose;
- Received the prescribed drug treatment at the prescribed time before first dose;
- Subjects who have participated in any drug clinical trials within 28 days prior to the first dose;
- ... and 14 more (see full listing online)

## Locations (51 total)

---

Beijing Anzhen Hospital Capital Medical University, Beijing, China  
Beijing Tiantan Hospital Capital Medical University, Beijing, China  
Beijing Tongren Hospital, Capital Medical University, Beijing, China  
... and 48 more locations